Emerging Novel Functional Imaging and Immunotherapy in Renal Cell Carcinoma and Current Treatment Sequencing Strategies After Immunotherapy
- PMID: 38875505
- DOI: 10.1200/EDBK_438658
Emerging Novel Functional Imaging and Immunotherapy in Renal Cell Carcinoma and Current Treatment Sequencing Strategies After Immunotherapy
Abstract
The management of renal cell carcinoma (RCC) has advanced significantly in the past two decades. Many promising functional imaging modalities such as radiolabeled tracer targeting carbonic anhydrase IX and prostate-specific membrane antigen are under development to detect primary kidney tumors, stage systemic disease, and assess treatment response in RCC. Immune checkpoint inhibitors targeting PD-1 and cytotoxic T-cell lymphocyte-4 have changed the treatment paradigm in advanced RCC. Trials investigating novel mechanisms such as LAG-3 immune checkpoint inhibition, chimeric antigen receptor T-cell therapies, and T-cell engagers targeting RCC-associated antigens are currently ongoing. With the rapidly changing treatment landscape of RCC, the treatment sequence strategies will continue to evolve. Familiarity with the toxicities associated with the therapeutic agents and how to manage them are essential to achieve optimal patient outcomes. This review summarizes the recent developments of functional imaging and immunotherapy strategies in RCC, and the evidence supports treatment sequencing.
Similar articles
-
Beyond conventional immune-checkpoint inhibition - novel immunotherapies for renal cell carcinoma.Nat Rev Clin Oncol. 2021 Apr;18(4):199-214. doi: 10.1038/s41571-020-00455-z. Epub 2021 Jan 12. Nat Rev Clin Oncol. 2021. PMID: 33437048 Free PMC article. Review.
-
Immune approaches beyond traditional immune checkpoint inhibitors for advanced renal cell carcinoma.Hum Vaccin Immunother. 2023 Dec 15;19(3):2276629. doi: 10.1080/21645515.2023.2276629. Epub 2023 Nov 10. Hum Vaccin Immunother. 2023. PMID: 37947202 Free PMC article. Review.
-
Combining Radiotherapy with Immunocheckpoint Inhibitors or CAR-T in Renal Cell Carcinoma.Curr Drug Targets. 2020;21(4):416-423. doi: 10.2174/1389450120666191017113051. Curr Drug Targets. 2020. PMID: 31625471
-
Current status of antigen-specific T-cell immunotherapy for advanced renal-cell carcinoma.Hum Vaccin Immunother. 2021 Jul 3;17(7):1882-1896. doi: 10.1080/21645515.2020.1870846. Epub 2021 Mar 5. Hum Vaccin Immunother. 2021. PMID: 33667140 Free PMC article. Review.
-
Novel immunotherapeutic strategies in development for renal cell carcinoma.Eur Urol. 2013 May;63(5):881-9. doi: 10.1016/j.eururo.2012.10.006. Epub 2012 Oct 12. Eur Urol. 2013. PMID: 23084331 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous